Get the Stockscreener App
1.62
98.41%
0.8035
Pre-market:
1.28
-0.34
-20.99%
BiomX Inc stock is traded at $1.62, with a volume of 69.10M.
It is up +98.41% in the last 24 hours and up +45.95% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$0.8165
Open:
$1.52
24h Volume:
69.10M
Relative Volume:
14.07
Market Cap:
$16.38M
Revenue:
-
Net Income/Loss:
$-36.20M
P/E Ratio:
-0.0678
EPS:
-23.8772
Net Cash Flow:
$-26.39M
1W Performance:
+333.16%
1M Performance:
+45.95%
6M Performance:
-65.53%
1Y Performance:
-83.56%
1-Day Range:
$1.43
$1.73
1-Week Range:
$0.38
$1.73
52-Week Range:
$0.3608
$14.71
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
1.62 | 8.26M | 0 | -36.20M | -26.39M | -23.88 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
PHGE Stock Jumps As BiomX Launches AI Command App - StocksToTrade
PHGE Stock Pops As BiomX Unveils AI Command App - timothysykes.com
PHGE Q4 2025 Earnings: EPS Misses Estimates Significantly, Stock Rises 10.5%Market Expert Watchlist - Newser
PHGE Q4 2025 Earnings: Severe EPS Miss as BiomX Continues Clinical DevelopmentSmart Trader Community - Newser
BiomX Inc. (PHGE) Q4 2025 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineInvestment Community - Newser
PHGE - Finviz
BiomX Inc. Q4 2025 Earnings: Large Earnings Miss Stirs Uncertainty, No Revenue ReportedProduct Revenue Analysis - Newser
PHGE Should I Buy - Intellectia AI
BiomX Inc. (PHGE) Q4 2025 Profit Warning: EPS $-8.17 Trails $-4.70Tangible Book Value - Newser
BiomX Inc. 1Q 2026: Net income $(19.14M), EPS $(7.38) — 10-Q Summary - TradingView
PHGE: Q1 2026 net loss was $19.1M amid a strategic pivot to defense and security tech - TradingView
BiomX (NYSE American: PHGE) pivots to defense tech amid Q1 2026 loss and going-concern risk - Stock Titan
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BiomX Inc. (PHGE) Jumps 6.1% as Earnings Loom Thursday - Meyka
BiomX Inc. (PHGE) Q4 2025 Disappoints — EPS $-8.17 Below $-4.70 ViewsCommunity Breakout Alerts - Newser
BiomX Inc. (PHGE) Stock Analysis: Falls -9.02%, Watching $0.50 2026-05-15Stock Idea Sharing Hub - Newser
BiomX Delays Quarterly Report Amid Strategic Shift - TipRanks
[NT 10-Q] BiomX Inc. SEC Filing - Stock Titan
BiomX Inc. (PHGE) Q4 2025 Earnings Miss: EPS $-8.17 vs $-4.70 ExpectedInstitutional Grade Picks - newser.com
BiomX Inc. (PHGE) affiliates report 82,618 shares; 33,934 warrants noted - Stock Titan
PHGE Stock Chart | BIOMX INC (NYSEARCA:PHGE) - ChartMill
TradingKey - TradingKey
PHGE Stock Price, Quote & Chart | BIOMX INC (NYSEARCA:PHGE) - ChartMill
BiomX (PHGE) Eps Diluted (TTM) - Zacks Investment Research
BiomX Company Profile & Introduction - Moomoo
BiomX subsidiary launches mobile command app for operators By Investing.com - Investing.com India
BiomX’s Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand - The Manila Times
BiomX subsidiary launches mobile command app for operators - Investing.com
Operators get AI command app that routes alerts in real time - Stock Titan
BiomX Reinvents Itself as Diversified Defense Technology Platform - TipRanks
BiomX (NYSE: PHGE) exits biotech and rebuilds as Israeli defense-tech holding - Stock Titan
BiomX Inc. 2025 Form 10-K/A Annual Report: Executive Team, Compensation, Governance & Financial Disclosures - Minichart
BiomX (NYSE: PHGE) details new board, equity plans and related deals - Stock Titan
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
BiomX announces 1-for-19 reverse stock split - MSN
All you need to know about BiomX (PHGE) rating upgrade to buy - MSN
What factors are influencing BiomX Inc. (PHGE) stock today | BiomX Inc. posts 73.7% EPS miss on zero Q4 revenueInvestor Call - Xã Thanh Hà
PHGE Technical Analysis | Trend, Signals & Chart Patterns | BIOMX INC (NYSEARCA:PHGE) - ChartMill
Is BiomX Inc. (PHGE) stock worth entering at this stage (-6.60%) 2026-04-18Trending Volume Leaders - Xã Thanh Hà
BiomX’s Zorronet Achieves 98% Success in Israel Railways Pilot, Secures AI-Powered Detection Framework Agreement - Minichart
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):